...
search icon
dnli-img

Denali Therapeutics Inc Share Price

DNLI
NSQ
$19.23
-$0.05
(-0.26%)
1D
Industry: Biotechnology Sector: Health Care

Denali Therapeutics Inc Analyst Forecast

Denali Therapeutics Inc Share Price Chart

Denali Therapeutics Inc Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$3.01B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
2.63M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.02
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$10.57 L
$23.77 H
$19.23

About Denali Therapeutics Inc, Common Stock

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California. more

Industry: BiotechnologySector: Health Care

Denali Therapeutics Inc Stock Returns

Time FrameDNLISectorS&P500
1-Week Return-2.34%0.72%-1.31%
1-Month Return9.7%1.27%0.78%
3-Month Return10.01%3.13%3.46%
6-Month Return29.76%15.81%6.19%
1-Year Return-11.75%8.89%11.68%
3-Year Return-33.09%20.79%71.21%
5-Year Return-69.64%35.89%74.81%
10-Year Return-10.35%138.44%256.59%

Denali Therapeutics Inc Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue335.66M48.66M108.46M330.53M-[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":14.5,"profit":true},{"date":"2022-12-31","value":32.31,"profit":true},{"date":"2023-12-31","value":98.47,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue212.62M5.61M7.03M16.73M7.79M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":2.64,"profit":true},{"date":"2022-12-31","value":3.31,"profit":true},{"date":"2023-12-31","value":7.87,"profit":true},{"date":"2024-12-31","value":3.67,"profit":true}]
Gross Profit335.66M48.66M108.46M330.53M(7.79M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":14.5,"profit":true},{"date":"2022-12-31","value":32.31,"profit":true},{"date":"2023-12-31","value":98.47,"profit":true},{"date":"2024-12-31","value":-2.32,"profit":false}]
Gross Margin100.00%100.00%100.00%100.00%-[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses272.94M344.41M449.21M527.23M487.34M[{"date":"2020-12-31","value":51.77,"profit":true},{"date":"2021-12-31","value":65.32,"profit":true},{"date":"2022-12-31","value":85.2,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":92.43,"profit":true}]
Operating Income62.72M(295.75M)(340.74M)(196.70M)(487.34M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-471.56,"profit":false},{"date":"2022-12-31","value":-543.3,"profit":false},{"date":"2023-12-31","value":-313.62,"profit":false},{"date":"2024-12-31","value":-777.04,"profit":false}]
Total Non-Operating Income/Expense18.48M9.19M29.55M96.54M129.27M[{"date":"2020-12-31","value":14.3,"profit":true},{"date":"2021-12-31","value":7.11,"profit":true},{"date":"2022-12-31","value":22.86,"profit":true},{"date":"2023-12-31","value":74.68,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income71.96M(291.16M)(325.97M)(145.19M)(422.70M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-404.61,"profit":false},{"date":"2022-12-31","value":-452.99,"profit":false},{"date":"2023-12-31","value":-201.77,"profit":false},{"date":"2024-12-31","value":-587.42,"profit":false}]
Income Taxes823.00K(575.00K)21.00K30.00K68.00K[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-69.87,"profit":false},{"date":"2022-12-31","value":2.55,"profit":true},{"date":"2023-12-31","value":3.65,"profit":true},{"date":"2024-12-31","value":8.26,"profit":true}]
Income After Taxes71.14M(290.58M)(325.99M)(145.22M)(422.77M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-408.49,"profit":false},{"date":"2022-12-31","value":-458.26,"profit":false},{"date":"2023-12-31","value":-204.15,"profit":false},{"date":"2024-12-31","value":-594.32,"profit":false}]
Income From Continuous Operations72.78M(290.58M)(325.99M)(124.43M)(422.77M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-399.25,"profit":false},{"date":"2022-12-31","value":-447.9,"profit":false},{"date":"2023-12-31","value":-170.96,"profit":false},{"date":"2024-12-31","value":-580.88,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income71.14M(290.58M)(325.99M)(145.22M)(422.77M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-408.49,"profit":false},{"date":"2022-12-31","value":-458.26,"profit":false},{"date":"2023-12-31","value":-204.15,"profit":false},{"date":"2024-12-31","value":-594.32,"profit":false}]
EPS (Diluted)0.26(2.39)(2.60)(1.08)(2.67)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-919.23,"profit":false},{"date":"2022-12-31","value":-1000,"profit":false},{"date":"2023-12-31","value":-415.38,"profit":false},{"date":"2024-12-31","value":-1026.92,"profit":false}]

Denali Therapeutics Inc Ratios

Denali Therapeutics Inc Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

DNLI
Cash Ratio 9.41
Current Ratio 9.79

Denali Therapeutics Inc Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

DNLI
ROA (LTM) -27.29%
ROE (LTM) -44.44%

Denali Therapeutics Inc Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

DNLI
Debt Ratio Lower is generally better. Negative is bad. 0.12
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.88

Denali Therapeutics Inc Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

DNLI
Trailing PE NM
Forward PE NM
P/S (TTM) 3643.65
P/B 3.16
Price/FCF NM
EV/R 2843.16
EV/Ebitda NM

FAQs

What is Denali Therapeutics Inc share price today?

Denali Therapeutics Inc (DNLI) share price today is $19.23

Can Indians buy Denali Therapeutics Inc shares?

Yes, Indians can buy shares of Denali Therapeutics Inc (DNLI) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in DNLI stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Denali Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Denali Therapeutics Inc (DNLI) via the Vested app. You can start investing in Denali Therapeutics Inc (DNLI) with a minimum investment of $1.

How to invest in Denali Therapeutics Inc shares from India?

You can invest in shares of Denali Therapeutics Inc (DNLI) via Vested in three simple steps:

  • Click on Sign Up or Invest in DNLI stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Denali Therapeutics Inc shares
What is Denali Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Denali Therapeutics Inc (DNLI) is $23.77. The 52-week low price of Denali Therapeutics Inc (DNLI) is $10.57.

What is Denali Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Denali Therapeutics Inc (DNLI) is

What is Denali Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Denali Therapeutics Inc (DNLI) is 3.16

What is Denali Therapeutics Inc dividend yield?

The dividend yield of Denali Therapeutics Inc (DNLI) is 0.00%

What is the Market Cap of Denali Therapeutics Inc?

The market capitalization of Denali Therapeutics Inc (DNLI) is $3.01B

What is Denali Therapeutics Inc's stock symbol?

The stock symbol (or ticker) of Denali Therapeutics Inc is DNLI

How Can Investors Use Denali Therapeutics Inc Share Price Data for Long-Term Investment Decisions?

Consider the share price of Denali Therapeutics Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Denali Therapeutics Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Denali Therapeutics Inc shares for Indian investors?

When investing in Denali Therapeutics Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Denali Therapeutics Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Denali Therapeutics Inc share price with other stocks in the same sector?

Rather than merely checking the share price of Denali Therapeutics Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Denali Therapeutics Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top